看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。' O. Z; j9 D# h- ?" j [
/ n" l' n; f ~
" k' P: P4 ]! z0 u4 Y4 U7 y% S3 C
Currently available feasibility data for possible combination strategies. 3 f! A1 ^& B0 W
————————————————————————————————
1 x' L7 _: u$ ?# c! H. TCombination Feasibility according to preliminary data ! |& j& }1 d- {# {3 D* U) A0 d
——————————————————————————————————
" X1 K4 J# b7 X1 R6 G4 jBevacizumab + sorafenib Yes, reduced dose
5 x3 N% T- b0 d1 n. c7 U1 RBevacizumab + sunitinib† No
" [! r; A( y' {1 QBevacizumab + temsirolimus Yes
! D( Q* v6 W: G u. z0 q- eBevacizumab + everolimus Yes ; W) l, W' K; }: t
Sorafenib + sunitinib ? . C9 g" O1 z' [
Sorafenib + temsirolimus Yes, reduced dose & K% Q4 U! I, H- r7 o9 k0 c3 x: b
Sorafenib + everolimus Yes, reduced dose : u6 d9 A) t) }* I
Sunitinib + temsirolimus† No
0 [- I; l& |. E: S% d. TSunitinib + everolimus ? 3 j1 K# h4 Q& Y! s4 w6 J% {
Temsirolimus + everolimus ? 6 T/ R$ ~+ \. e
————————————————————7 z, t0 C0 O, h! Z
†Led to US FDA warning.2 d' J9 o6 c5 Y
?: As yet unattempted combination.
2 G* P- O& ?! L) F |